Side by side

Compare peptides.

See why people discuss them, what the evidence supports, and where amount information comes from.

Choose two compounds

Add up to four if you need to. Evidence labels apply to specific claims and products.

Compare more (up to four)

Tissue & skin

Wolverine

Wolverine combines BPC-157 5 mg + TB-500 5 mg in one 10 mg vial. People discuss it for recovery; benefits of this exact blend are unproven.

Why people are interested

People call BPC-157 plus TB-500 the Wolverine stack when discussing tendon, joint and workout recovery. A blend name is not a standardized medicine or proof that combining ingredients helps.

What the research supports

The strongest claims about injury repair remain largely preclinical. A small uncontrolled knee-pain series included BPC-157 plus TB4, but did not test this 5 mg + 5 mg product or prove that a combination works better.

Amount source summary

Two individual reports · not a dosing consensus

Whole-blend amounts in separate accounts: 0.5 mg and 1 mg

How often: Each writer reported daily use

These are two separate anecdotes, not low/high recommendations. The 0.5 mg account reported palpitations and vivid dreams. Neither verifies this supplier’s product or establishes a safe dose.Schedule, route & sources →
Read the full Wolverine profile and sources →
Metabolic & appetite

Tirzepatide

Tirzepatide acts on GIP and GLP-1 receptors. It has been studied in human medicine products for blood sugar and metabolic effects.

Why people are interested

Tirzepatide is well known because prescription versions are used for type 2 diabetes, chronic weight management, and certain sleep-apnea patients. JD-2TR is a seller code associated with tirzepatide in listed batch reports.

What the research supports

The strongest evidence belongs to manufactured prescription tirzepatide products studied in clinical trials. FDA approval applies to those products and specific indications, not automatically to a research-only JD-2TR vial.

Amount source summary

Selected public accounts · not a dosing consensus

Reported amount + frequency: 2.5 mg — Once weekly

How often: Each amount stays paired with its own reported schedule.

One self-report is not a recommended regimen. A prescription label applies to its named medicine, not an independently sold research vial.Schedule, route & sources →
Read the full Tirzepatide profile and sources →

FDA-approved uses belong to named prescription products and indications; they do not transfer to an online research vial. Human, animal, cell, and anecdotal evidence are different. How we check sources →